Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug SPY002-072 aims to tame multiple inflammatory joint diseases

NCT ID NCT07148414

Ongoing Disease control Sponsor: Spyre Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests an experimental drug called SPY002-072 in 285 adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis. Participants receive either the drug or a placebo, and researchers measure changes in disease activity over time. The goal is to see if the drug can safely reduce joint pain, swelling, and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SPY002-072 (also called SPY072), an experimental drug
What this could lead to
If successful, this could lead to a new treatment option for people with inflammatory rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
What could go wrong
This is an early Phase 2 proof-of-concept study, so results are not yet proven. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis Collagen Diseases pleomorphic adenoma psoriatic arthritis rheumatic disorder rheumatoid arthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AXIAL SPONDYLOARTHRITIS AXSPA PSA (PSORIATIC ARTHRITIS) PSORIATIC ARTHRITIS RHEUMATIC DISEASES RHEUMATIC JOINT DISEASE RHEUMATOID ARTHRITIS RHEUMATOLOGIC DISEASE

Contacts and locations

Locations

  • Site 102

    Tomball, Texas, 77377, United States

  • Site 103

    Tomball, Texas, 77375, United States

  • Site 104

    Duncansville, Pennsylvania, 16635, United States

  • Site 105

    Corpus Christi, Texas, 78404, United States

  • Site 106

    Ormond Beach, Florida, 32174, United States

  • Site 107

    Whittier, California, 90602, United States

  • Site 108

    Tujunga, California, 91042, United States

  • Site 109

    Hialeah, Florida, 33016, United States

  • Site 110

    Tampa, Florida, 33614, United States

  • Site 111

    Covina, California, 91722, United States

  • Site 112

    Upland, California, 91786, United States

  • Site 113

    Avondale, Arizona, 85392, United States

  • Site 114

    Chula Vista, California, 91910, United States

  • Site 115

    Aventura, Florida, 33180, United States

  • Site 116

    Willowbrook, Illinois, 60527, United States

  • Site 118

    Tucson, Arizona, 85748, United States

  • Site 119

    Rockville, Maryland, 20850, United States

  • Site 120

    Irving, Texas, 75039, United States

  • Site 201

    Chisinau, MD-2025, Moldova

  • Site 202

    Chisinau, MD-2025, Moldova

  • Site 301

    Tbilisi, K'alak'i T'bilisi, 0159, Georgia

  • Site 302

    Kutaisi, 4600, Georgia

  • Site 303

    Tbilisi, K'alak'i T'bilisi, 0102, Georgia

  • Site 304

    Tbilisi, K'alak'i T'bilisi, 0112, Georgia

  • Site 305

    Tbilisi, K'alak'i T'bilisi, 0186, Georgia

  • Site 306

    Tbilisi, 0186, Georgia

  • Site 307

    Tbilisi, K'alak'i T'bilisi, 0172, Georgia

  • Site 308

    Batumi, 6010, Georgia

  • Site 401

    Krakow, Lesser Poland Voivodeship, 30-363, Poland

  • Site 402

    Opole, Opole Voivodeship, 45-819, Poland

  • Site 403

    Warsaw, Masovian Voivodeship, 02-677, Poland

  • Site 404

    Lodz, Lódzkie, 91-363, Poland

  • Site 405

    Warszawa, Pomeranian Voivodeship, 00-874, Poland

  • Site 406

    Gdynia, Pomeranian Voivodeship, 81-384, Poland

  • Site 407

    Nowa Sól, Lubusz Voivodeship, 67-100, Poland

  • Site 408

    Elblag, Warmian-Masurian Voivodeship, 82-300, Poland

  • Site 502

    Pleven, Pleven, 5803, Bulgaria

  • Site 503

    Lovech, Lovech, 5500, Bulgaria

  • Site 504

    Varna, Varna, 9000, Bulgaria

  • Site 505

    Plovdiv, Plovdiv, 4003, Bulgaria

  • Site 506

    Plovdiv, Plovdiv, 4000, Bulgaria

  • Site 601

    Santander, Madrid, 39008, Spain

  • Site 602

    A Coruña, A Coruña, 15006, Spain

  • Site 603

    Seville, Sevilla, 41010, Spain

  • Site 604

    Chiclana de la Frontera, Cadiz, 11139, Spain

  • Site 701

    Uherské Hradiště, Zlín, 68601, Czechia

  • Site 702

    Moravská Ostrava, Ostrava-město, 702 00, Czechia

  • Site 703

    Prague, Praha, Hlavní Mesto, 140 00, Czechia

  • Site 704

    Pardubice, Pardubice Region, 530 02, Czechia

  • Site 705

    Prague, Praha, Hlavní Mesto, 130 00, Czechia

  • Site 706

    Hlučín, Hlučín, 748 01, Czechia

  • Site 801

    Vinnytsia, Vinnytsia Oblast, 21028, Ukraine

  • Site 802

    Vinnytsia, Vinnytsia Oblast, 21029, Ukraine

  • Site 803

    Kyiv, Kyiv Oblast, 2125, Ukraine

  • Site 804

    Kyiv, Kyiv Oblast, 04050, Ukraine

  • Site 805

    Kyiv, Kyiv Oblast, 4106, Ukraine

  • Site 806

    Kyiv, Kyiv Oblast, 03049, Ukraine

  • Site 807

    Lviv, Lviv Oblast, 79044, Ukraine

  • Site 808

    Ternopil, Ternopil Oblast, 46002, Ukraine

  • Site 809

    Chernihiv, Chernihiv Oblast, 14029, Ukraine

  • Site 810

    Ternopil, Ternopil Oblast, 46002, Ukraine

  • Site 811

    Zhytomyr, Zhytomyr Oblast, 10002, Ukraine

  • Site 812

    Vinnytsia, Vinnytska, 21000, Ukraine

  • Site 813

    Kyiv, Kyiv Oblast, 02091, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.